Progesterone-Mediated Inhibition of the GnRH Pulse Generator: Differential Sensitivity as a Function of Sleep Status.
Su Hee Kim, Jessica A Lundgren, Ruchi Bhabhra...
https://pubmed.ncbi.nlm.nih.gov/29300925/Actively Recruiting
Led by University of Virginia · Updated on 2025-08-05
36
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are investigating how progesterone affects luteinizing hormone LH pulse frequency during waking and sleep periods in mid- to late pubertal girls, both with and without hyperandrogenism HA. The study aims to find out if progesterone reduces waking LH pulse frequency more than sleep-associated LH pulse frequency in girls without HA, and whether this effect is less in girls with HA. The study is a randomized, placebo-controlled, double-blind crossover trial involving mid- to late pubertal girls at Tanner breast stage 3 or higher but no more than 2 years after menarche. Participants will attend two 18-hour clinical research unit admissions across separate menstrual cycles, receiving either oral micronized progesterone 0.8 mgkg at 7 AM, 3 PM, 11 PM, and 7 AM or placebo. Blood samples will be collected every 10 minutes overnight to measure LH pulses and other hormones. After at least two months, participants will switch treatments for the second admission. Participants will be closely monitored throughout the study with frequent blood tests to characterize LH secretion patterns. The main measure is LH pulse frequency while awake, with sleep LH pulse frequency as a secondary measure. The study includes detailed hormone analysis and statistical modeling to compare effects between girls with and without HA. The total participation includes two inpatient admissions separated by at least two months.
CONDITIONS
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
M
Melissa Gilrain
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Virginia
Lead Sponsor
National Institutes of Health (NIH)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Micronized progesterone suspension | Placebo |
|---|---|---|
| What it is | A suspension containing micronized progesterone, a natural hormone, given at scheduled intervals to assess its acute effects on luteinizing hormone pulse frequency. | A comparator arm using inactive placebo, containing no hormones or active substances. |
| Role in trial | Tests whether short-term progesterone administration suppresses or modifies luteinizing hormone pulse patterns during wake and sleep in adolescent girls. | Serves as the comparison condition to distinguish effects of progesterone from natural fluctuations without hormone input. |
| Primary use or goal | To determine whether acute progesterone exposure suppresses luteinizing hormone pulse frequency in mid-to-late pubertal girls, including those with and without hyperandrogenism. | To serve as a control that allows measurement of baseline hormone pulse frequency changes without progesterone administration. |
| How it is given or performed | Participants receive micronized progesterone at 0.8 mg/kg, administered at 0700, 1500, and 2300 hours, then again at 0700 the following day. | Participants are given placebo suspensions using the same timing schedule as the progesterone arm. |
| Evidence status | Published research shows that progesterone can acutely suppress hypothalamic hormone pulse frequency in adolescent girls, with effects varying between wake and sleep states. | No significant suppression of hormone pulse frequency is expected with placebo, as it does not contain active progesterone. |
| Important limitations | Effects observed are short-term and may not predict long-term hormone regulation or clinical outcomes. Study population is limited to adolescent girls, which may not generalize to boys or younger/older age groups. | Placebo results provide only a baseline for acute hormone patterns. No long-term or therapeutic effect is assessed and no physiological change is expected. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Each treatment period lasts approximately 18 hours, with two treatment admissions separated by at least 2 months
Participants receive either micronized progesterone or placebo in a randomized, double-blinded crossover design, with dosing at 0700, 1500, 2300, and 0700 h during each Clinical Research Unit admission. Blood samples are collected every 10 minutes from 1800 to 1200 h to measure hormone levels.
2 Clinical Research Unit admissions of 18 hours each, separated by at least 2 months
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Su Hee Kim, Jessica A Lundgren, Ruchi Bhabhra...
https://pubmed.ncbi.nlm.nih.gov/29300925/University of Virginia
Lead Sponsor
National Institutes of Health (NIH)
Collaborating Sponsor